BRAF and non-small cell lung carcinoma: What is certain is that the presence of the BRAF V600 mutation in NSCLC is a predictive marker of response to specific RAF inhibitors, such as vemurafenib or dabrafenib, in monotherapy or in combination with an MEK inhibitor [98,99,100].